Seeking Alpha

BioStocksElite

 
View as an RSS Feed
View BioStocksElite's Comments BY TICKER:
Latest  |  Highest rated
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    Athersys completed patient enrollment for the UC study in December 2013.

    http://bit.ly/PSyBzr
    Apr 9, 2014. 04:07 PM | Likes Like |Link to Comment
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    Him and Louis appear to be the same person... look at their followers on twitter... they are a scam.
    Apr 7, 2014. 07:06 PM | 9 Likes Like |Link to Comment
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    Funny how this author... and louisdematteis ... the author who wrote the last ridiculous article.... both have virtually no following on twitter.... and both follow the same dozen people. Personally I think they are the same person who have been paid to write poor articles.
    Apr 7, 2014. 07:05 PM | 11 Likes Like |Link to Comment
  • Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price [View article]
    You missed an important point during the conference call. Pfizer is interested in other indications for MultiStem. With positive data from the IBD study, Pfizer's interest in the company is going to go up substantially. Furthermore, positive P2 data will expedite approval in Japan for IBD as well. Positive P2 data will be a major catalyst for this company.
    Apr 7, 2014. 11:59 AM | 15 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Perhaps you are the only one on the other side of the boat quite simply because you are wrong. A lot of people have spent hours upon hours of doing research and due diligence on Athersys and have been following the company for some time... which substance clearly is not reflected in your article.

    And yes, I am willing to bet most who have posted here against your article are long. I am also willing to bet by your article that you are not long or are short. Either way, both are very basic assumptions.

    As for the "amazing show of bullishness"... again, a lot of people have done a lot of due diligence. If MultiStem shows efficacy in the IBD and stroke study, Athersys is going to be worth a lot more money this year discounting everything else that is going on with them. MultiStem with their MAPC platform could potentially be a game changer for the standard of care in medicine. This is one of those stocks that can easily run huge if MultiStem meets primary end points.
    Feb 26, 2014. 07:19 AM | 7 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    For further clarification.... studies have shown that MAPCs are superior to MSC's. Again, ANOTHER major flaw in your article. Published in "Advanced Studies in Biology, Vol. 1, 2009, no. 1, 25 - 35"

    The study conclusion "We found that MSCs gradually lost its multiple differentiation potential and phenotype with the increase of passages, whereas MAPCs well retained pluripotency. Therefore, MAPCs may hold a greater promise in the future clinical application than MSCs."

    http://bit.ly/1hOICq5
    Feb 26, 2014. 07:05 AM | 3 Likes Like |Link to Comment
  • Recent Developments Do Not Justify Athersys' Doubling Since December [View article]
    Horrible article. You really missed the boat. Here are the reasons why Athersys is presently undervalued at the current $4 stock price:
    1.) Athersys now has $50M in cash and only burns $4-5 per quarter and no debt
    2.) Athersys now has a market cap of $250M, competitor Mesoblast who appears to have an inferior product MAPC v. MSC has a 1.9 BILLION market cap which is 7x Athersys' present valuation, leading me to believe Athersys is still grossly undervalued
    3.) Athersys has the most advanced stroke program. MultiStem for stroke is potentially worth $15-30 Billion annually, there is a huge unmet market for stroke with only 1 therapy presently available (tPa) and said drug is often missed since it must be administered within a few hours of stroke onset
    4.) Athersys has the potential to get MultiStem approved for stroke in Japan with a conditional approval with additional studies to be performed at a later date, this means that Athersys can become very profitable sooner rather than later
    5.) The new developments in Japan about expediting regenerative medicine therapy creates a huge potential opportunity for getting MultiStem approved for other therapies in Japan
    6.) Athersys' partnership with RTIX should equate to milestone payments upwards of $30M not including royalties from sales for their bone allograft system
    7.) The upcoming IBD results in April/May will provide significant validation for MultiStem and its value, and is the same for the stroke results following thereafter
    8.) Athersys is moving forward with their GvHD phase 2/3 study in the US which will add significant value... and MultiStem for GvHD may get expedited approval in Japan
    9.) Athersys is expected to commence P2 study for AMI and this too can potentially get expedited approval in Japan
    10.) Athersys is continually evaluating MultiStem for solid organ transplant study that is ongoing, PVD / PAD / CLI, congestive heart failure, traumatic brain injury, spinal cord injury
    11.) MultiStem is being evaluated in a patch form for diabetic foot ulcers
    http://bit.ly/1c624Qw
    12.) Athersys has a potential blockbuster weight loss drug which they may partner or do it alone
    *** and there is more... but you get the picture.

    So the question is, is a $250M market cap on a company where they have potentially a dozen applications worth billions EACH too high when they have multiple significant catalysts and events coming up? If you answer yes to that you are simply an idiot. Mesoblast is trading 7x the market cap of Athersys with potentially a less effective platform. The current price of $4 is dirt cheap and Athersys should be trading $7-8 on positive IBD data and over $10 on positive stroke data. Assuming positive IBD and stroke data, with expedited approval in Japan, this small cap biotech stock can become a very profitable company much sooner than investors originally expected. It also gives Athersys a huge buyout potential on positive data.
    Feb 25, 2014. 07:12 PM | 24 Likes Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    Terminating management usually is a bad thing.
    Jan 22, 2014. 02:13 PM | 2 Likes Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    Ive looked at ACTC and it is currently trading at .06 and it literally has billions of shares which I have never seen before in another biotech company. ACTC also has only about $7M in the bank which is concerning for dilution. Their ongoing studies are also limited to the eyes which has a significantly smaller market potential compared to IBD, stroke, heart disease etc. I have been keeping my eye on most stem cell companies because of the potential but still consider ATHX the front runner because of their potential. Thats just my opinion.
    Jan 22, 2014. 08:21 AM | 4 Likes Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    My general buyout of $24-26 does include favorable data for stroke. As I said above, the company would still have to complete Phase 3 studies and get approval upon favorable results so there is risk there. If things move along quickly in Japan and they get MultiStem to the marketplace then that is a complete game changer and Athersys is easily a $100 stock.
    Jan 22, 2014. 08:14 AM | 1 Like Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    That is just my general thought for short term since MultiStem still has to complete Phase 3 studies and get approval. If MultiStem gets onto the marketplace for multiple indications then that is a game changer because of the massive potential. Athersys at that time will easily be a $100 stock (no exaggeration).
    Jan 22, 2014. 08:11 AM | 1 Like Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    Nice article. As always, well written.
    Jan 22, 2014. 08:09 AM | 1 Like Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    Thank you. I agree that the MAPCs are the best technology out there. I wholly agree with all of your articles as well.
    Jan 22, 2014. 08:07 AM | 1 Like Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    I personally think there is a buyout potential (as with all biotech stocks). The market potential for regenerative medicine is huge if it works. Athersys, in my opinion, has the best technology out there with their MAPCs. However, they still do not have an approved product. There still is the risk that MultiStem won't make it to the marketplace. If a large pharma came along and offered a significant buyout that provided shareholders 6x the current value of the stock I would bet many of them would be for it... only because the risk is still there. On the other hand, if Athersys avoids a buyout and they get MultiStem to the marketplace for some indications and are pushing for others, we would know that MultiStem works and Im assuming shareholders would not be for selling the company. There are always a lot of unknowns in the biotech industry and for Athersys it is just a matter of timing and risk assessment in my opinion.
    Jan 22, 2014. 08:05 AM | 2 Likes Like |Link to Comment
  • Athersys, Inc. And The Future Of Regenerative Medicine [View article]
    I agree with Mike below (and Mike, thank you for the link). The legislative changes in Japan are very new. However, management from Athersys has been to Japan a few confirmed times lately and has expeditiously locked in patents there. I believe based on the companies aggressive response to the changes in Japan that they are really focused on it. Management has also positively publicly commented on this as well.
    Jan 22, 2014. 08:00 AM | 1 Like Like |Link to Comment
COMMENTS STATS
30 Comments
128 Likes